Evaluating the risks and benefits of phase II and III cancer clinical trials: a look at Institutional Review Board members in the Netherlands.
Van Luijn
H E M
HE
Department of Philosophy, Vrije Universiteit, Amsterdam, The Netherlands.
Musschenga
A W
AW
Keus
R B
RB
Aaronson
N K
NK
D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D028744:Ethics Committees, Research; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009426:Netherlands; D010358:Patient Participation / Q000523:psychology; D018570:Risk Assessment / Q000379:methods*